Short answer
Axogen, Inc. (AXGN) filed its fiscal 2025 10-K annual report with the SEC on Feb 24, 2026. It reported revenue of $225M (+20.2% year over year) and net income of −$16M.
- Top risk flagged: Regulatory risk: FDA accelerated approval of Avance Products contingent on confirmatory trials with milestones through 2031; failure may cause withdrawal or restrictions
FY2025 key financial metrics · XBRL
- Revenue
- $225M
- +20.2% YoY
- Net income
- −$16M
- −57.6% YoY
- Operating margin
- -3.5%
- −1.7 pp YoY
- Gross margin
- 74.3%
- −1.5 pp YoY
- EPS (diluted)
- −$0.34
- −47.8% YoY
- ROE
- -12.2%
- −2.6 pp YoY
- Operating cash flow
- $812,000
- −82.1% YoY
Source: XBRL data from the Axogen, Inc. (AXGN) FY2025 10-K on SEC EDGAR. USD.
Axogen, Inc. FY2025 10-K analysis
AI summary of each section, grounded in the filing text
Business Overview
- Core business: Development and commercialization of innovative peripheral nerve regeneration and repair technologies
- New product: FDA-approved Avance® acellular nerve scaffold (December 3, 2025), launching Q2 2026, replacing Avance® Nerve Graft
- Strategic shift: Transition of Avance Products from Section 361 human tissue to licensed biologic under Section 351 with post-marketing study commitments
- Quantitative highlight: Avance Nerve Graft with 17+ years clinical use and over 120,000 implants, US peripheral nerve injury TAM estimated at >$5.6 billion
- Noteworthy fact: Launch of Avive+ Soft Tissue Matrix in June 2024, an amniotic membrane allograft under FDA HCT/P regulations subject to future oversight changes
Management Discussion & Analysis
- Revenue $225.2M, up 20.2% YoY from $187.3M driven by unit volume, price, and product mix changes
- Gross margin 74.3% vs 75.8% YoY, gross profit $167.4M up 17.9% from $142.0M, impacted by $1.9M one-time FDA BLA costs
- Sales & marketing best performer: $97.7M (+24.6%), R&D $32.9M (+18.4%), G&A $44.6M (+14.2%)
- Cash, cash equivalents, restricted cash, and investments $45.5M up $6.0M YoY; $133.3M net proceeds from Jan 2026 equity raise, $69.7M used to repay term loan
- 2026 outlook positive: new Level 3 nerve procedure code boosts reimbursement 35-40%, expanded insurance coverage to 19.8M lives, FDA approval dependency noted as key risk
Risk Factors
- Regulatory risk: FDA accelerated approval of Avance Products contingent on confirmatory trials with milestones through 2031; failure may cause withdrawal or restrictions
- Operational risk: Avance manufacturing relies on variable donated cadaveric tissue, causing potential lot failures, product recalls, and supply shortages
- Geopolitical/macroeconomic risk: Healthcare reimbursement uncertainty; CMS reimbursement changes in 2026 increased outpatient nerve repair payments by 96%-221%, impacting commercial payor coverage
- Competitive risk: Market acceptance dependent on overcoming surgeon concerns of allograft disease transmission and competing surgical techniques
- Financial risk: Dependence on six products, with Avance generating ~60% revenue; disruption in Avance sales could materially impact financials
Generated from the filing text; verify against the original. How to read a 10-K
Ask about this 10-K
Compare years, dig into a risk factor or check the numbers against insider trades and fund holders.